Protagonist Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
NEWARK, CA / ACCESSWIRE / January 3, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh...
Year: 2024
Assertio Holdings, Inc. Announces Leadership Transition
Dan Peisert Stepping Down as CEO Board member Heather Mason Appointed Interim CEO LAKE FOREST, Ill., Jan. 03, 2024 (GLOBE...
Cannabix Technologies Files Patent for Proprietary Laboratory Drug Analysis Device
Fig. 1 Cannabix “MS Breath Sampler (MSBS)” technology coupled with Thermo TSQ Ultra Fig. 2 Cannabix updated Breath Collection Unit...
Tenaya Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with...
Xenon Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
VANCOUVER, British Columbia, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that...
NightHawk Biosciences Commences Work on Multi-Million-Dollar Development and Manufacturing Agreement For a Leading National University
Scorpius subsidiary to manufacture novel biologic targeting substance use disorderDURHAM, N.C., Jan. 03, 2024 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE...
Investigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals’ Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient Enrollment
Additional Ewing Sarcoma Patient in Company’s Phase 1/2 Sarcoma Trial Achieves Partial Response; Objective Response Rate Among First-Relapse Ewing Patients...
Wave Life Sciences to Present at 42nd Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed...
Sofwave Medical Receives 510(k) Marketing Clearance for Pure Impact™ Strength and Muscle Toning Body Module Utilizing PlyoPulse™ EMS Technology
Pure Impact™ with PlyoPulse™ technology is a direct add-on Body module to the existing FDA cleared Sofwave medical aesthetic device...
Vericel to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024
CAMBRIDGE, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine...
CRISPR Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
ZUG, Switzerland and BOSTON, Jan. 03, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating...
Akero Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for...
AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer’s and Parkinson diseases
AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson diseases ABATE Phase 1b/2 AD...
ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Providing Outlook for 2024
WESTON, Fla., Jan. 03, 2024 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company...
MaxCyte and Lion TCR form Partnership to Support Global Expansion of Lion TCR’s TCR-T Cell Pipeline
Lion TCR to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to develop and scale TCR-T cell therapies for solid...
Ardelyx to Provide Company Update on IBSRELA® and Host a KOL Discussion on the IBS-C Landscape on Monday, January 8
Live event and webcast scheduled for 7:00 p.m. ET / 4:00 p.m. PTWALTHAM, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) --...
4DMT and Arbor Biotechnologies Establish Partnership to Co-Develop and Co-Commercialize Next-Generation Genetic Medicines for CNS Diseases
Partnership brings together two leaders in next-generation genetic medicines to engineer, co-develop and co-commercialize (50:50 profit share) AAV-delivered CRISPR/Cas-based therapeutics...
Vaxxinity to Present at the 2024 J.P. Morgan Healthcare Conference
CAPE CANAVERAL, Fla., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of...
Noema Pharma to Present at Two Upcoming Conferences
BASEL, Switzerland, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS)...
Pacira BioSciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
TAMPA, Fla., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will present at...